
GeoVax Labs, Inc.
NASDAQ:GOVX
1.08 (USD) • At close April 1, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | GeoVax Labs, Inc. |
Symbool | GOVX |
Munteenheid | USD |
Prijs | 1.08 |
Beurswaarde | 14,946,660 |
Dividendpercentage | 0% |
52-weken bereik | 1.03 - 11.18 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. David Alan Dodd |
Website | https://www.geovax.com |
An error occurred while fetching data.
Over GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)